RG 7916

Drug Profile

RG 7916

Alternative Names: RG7916; RO 7034067

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PTC Therapeutics
  • Developer PTC Therapeutics; Roche
  • Class Small molecules
  • Mechanism of Action Survival of motor neuron 2 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Spinal muscular atrophy

Most Recent Events

  • 12 Oct 2017 Chugai Pharmaceutical plans a phase II trial for Spinal muscular atrophy in Japan, Belgium, France, Germany and Italy (JapicCTI-173722)
  • 03 Oct 2017 RG 7916 receives Fast Track designation for Spinal muscular atrophy [PO] (In adolescents, Treatment-experienced, In adults) in USA
  • 03 Oct 2017 Interim efficacy data from part 1 of the phase II SUNFISH trial in Spinal muscular atrophy released by PTC Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top